

09/88/326
Att# 8

WEST Search History

DATE: Thursday, June 20, 2002

Set Name Query
side by sideHit Count Set Name
result set

DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ

L4	l1 with l2 with L3	161	L4
L3	transfect\$ or transduct\$	38825	L3
L2	dna or rna or plasmid or oligonucleotide or polynucleotide or (nucleic acid)	172154	L2
L1	vascula\$ or artery or arteries or arteriole or vein or venous or (blood vessel)	139100	L1

END OF SEARCH HISTORY

Search Results - Record(s) 1 through 50 of 161 returned.

1. 20020077287. 11 May 01. 20 Jun 02. 28 human secreted proteins. Ruben, Steven M., et al. 514/12; 435/183 435/320.1 435/325 435/69.1 530/350 536/23.2 A61K038/17 C07H021/04 C12N009/00 C12P021/02 C12N005/06 C07K014/435.

2. 20020076797. 04 Jun 01. 20 Jun 02. Purified and isolated piwi family genes and gene products and methods using same. Lin, Haifan. 435/226; 435/320.1 435/325 435/6 435/69.1 536/23.2 C12N009/64 C12Q001/68 C07H021/04 C12P021/02 C12N005/06.

3. 20020076756. 11 May 01. 20 Jun 02. 28 human secreted proteins. Ruben, Steven M., et al. 435/69.1; 435/320.1 435/325 530/350 536/23.5 C12P021/02 C12N005/06 C07H021/04 C07K014/435.

4. 20020076705. 30 Mar 01. 20 Jun 02. 31 human secreted proteins. Ruben, Steven M., et al. 435/6; 435/320.1 435/325 435/69.1 536/23.2 C12Q001/68 C07H021/04 C12N005/06 C12P021/02.

5. 20020068319. 08 Mar 01. 06 Jun 02. 32 human secreted proteins. Ni, Jian, et al. 435/69.1; 435/183 435/325 435/7.1 530/388.1 536/23.5 C12P021/02 C12N005/06 G01N033/53 C07H021/04 C12N009/00.

6. 20020064829. 14 Jun 01. 30 May 02. Human tumor necrosis factor delta and epsilon. Yu, Guo-Liang, et al. 435/69.1; 424/145.1 435/320.1 435/325 530/351 530/388.23 536/23.5 A61K039/395 C07K014/525 C07K016/24 C07H021/04.

7. 20020061862. 13 Nov 01. 23 May 02. Inducible nitric oxide synthase for treatment of disease. Billiar, Timothy R., et al. 514/44; 424/450 435/320.1 435/456 A61K048/00 A61K009/127 C12N015/861.

8. 20020061834. 09 Feb 01. 23 May 02. Human G-protein Chemokine receptor (CCR5) HDGNR10. Rosen, Craig A., et al. 514/1; 435/320.1 435/325 435/69.1 530/350 536/23.5 A61K031/00 C07H021/04 C07K014/705 C12N005/06 C12P021/02.

9. 20020061522. 28 Feb 01. 23 May 02. 1983, 52881, 2398, 45449, 50289, and 52872 novel G protein-coupled receptors and uses therefor. Glucksmann, Maria Alexandra, et al. 435/6; 435/320.1 435/325 435/7.1 530/350 536/23.5 C12Q001/68 G01N033/53 C07H021/04 C12N005/06 C07K014/705.

10. 20020061295. 08 Jun 01. 23 May 02. Myocardial grafts and cellular compositions useful for same. Field, Loren J.. 424/93.21; 424/93.7 A61K048/00.

11. 20020054864. 02 Oct 01. 09 May 02. Stimulation of cell-mediated immune responses by targeted particulate genetic immunization. Falo, Louis D. JR., et al. 424/93.2; 424/93.21 435/320.1 435/456 A61K048/00 C12N015/86 C12N015/867.

12. 20020048786. 09 Feb 01. 25 Apr 02. Human G-protein Chemokine Receptor HDGNR10. Rosen, Craig A., et al. 435/69.1; 424/130.1 435/325 435/7.2 514/12 536/23.5 G01N033/53 G01N033/567 A61K038/00 C07H021/04 C12P021/06 A61K039/395 C12N005/02 C12N005/00.

13. 20020045158. 08 Feb 01. 18 Apr 02. Cells for drug discovery. Case, Casey. 435/4; 435/325 C12Q001/00 C12N005/06.

14. 20020039786. 19 Jan 01. 04 Apr 02. Liver tissue source. Reid, Lola M., et al. 435/325; 435/366 435/372 C12N005/08 C12N005/06.

15. 20020039572. 18 Jun 99. 04 Apr 02. CHIMERIC MAMMALIAN ALLANTOIS. DOWNS, KAREN M.. 424/93.21; 424/93.2 424/93.7 800/4 A61K048/00.

16. 20020037279. 17 Jul 98. 28 Mar 02. DELIVERY OF BIOACTIVE COMPOUNDS TO AN ORGANISM. VANDENBURGH, HERMAN H.. 424/93.21; 424/93.2 435/29 435/320.1 435/325 435/455 A61K048/00 C12Q001/02 C12N005/08.

17. 20020028817. 09 Apr 01. 07 Mar 02. PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same. Levitzki, Alexander, et al. 514/250; 514/267 544/250 544/251 544/344 A61K031/519 A61K031/4985 C07D471/12.

18. 20020028449. 01 Dec 00. 07 Mar 02. 26 Human secreted proteins. Ruben, Steven M., et al. 435/6; 435/183 435/69.1 530/388.1 536/23.1 C12Q001/68 C07H021/02 C07H021/04 C12P021/02 C12N009/00.

19. 20020028193. 15 Feb 01. 07 Mar 02. Recombinant beta2-adrenergic receptor delivery and use in treating airway and vascular diseases. Cornett, Lawrence E., et al. 424/93.21; 435/320.1 514/44 A61K048/00.

20. 20020026235. 15 Oct 01. 28 Feb 02. Prosthetic grafts. Anderson, Diane Lee, et al. 623/1.41; 623/1.42 623/903 A61F002/06.

21. 20020026040. 16 Jul 01. 28 Feb 02. 49 human secreted proteins. Moore, Paul A., et al. 536/23.1; 435/6 530/300 C12Q001/68 C07H021/02 C07H021/04 C07K002/00 C07K004/00 C07K005/00 C07K007/00 C07K014/00 C07K016/00 C07K017/00 A61K038/00.

22. 20020026037. 10 Feb 99. 28 Feb 02. VASCULAR ENDOTHELIAL GROWTH FACTOR 3 ANTIBODIES. HU, JING-SHAN, et al. 530/389.2; 424/187.1 C12P021/02 A61K039/21 C07K016/00.

23. 20020025553. 01 Dec 00. 28 Feb 02. Transforming growth factor alpha HIII. Wei, Ying-Fei. 435/69.1; 435/325 435/7.1 530/399 536/23.5 C12P021/02 G01N033/53 C07H021/04 C12N005/06 C07K014/61.

24. 20020022233. 17 Oct 01. 21 Feb 02. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules. Wells, Jim, et al. 435/6; 435/7.1 435/7.92 C12Q001/68 G01N033/53 G01N033/537 G01N033/543.

25. 20020013288. 15 Aug 01. 31 Jan 02. Enhancement of vascular function by modulation of endogenous nitric oxide production or activity. Cooke, John P., et al. 514/44; 435/320.1 435/455 A61K048/00 C12N015/00.

26. 20020012966. 25 Jan 01. 31 Jan 02. 18 Human secreted proteins. Shi, Yanggu, et al. 435/69.1; 435/183 435/325 530/350 536/23.1 C12P021/02 C07H021/04 C12N009/00 C12N005/08.

27. 20020001574. 30 Dec 97. 03 Jan 02. PROCESS OF DELIVERING A POLYNUCLEOTIDE TO A MUSCLE CELL VIA THE VASCULAR SYSTEM. WOIFF, JON A., et al. 424/93.1; 514/44 A61K048/00.

28. 20010041346. 14 Jul 99. 15 Nov 01. METHOD FOR ASSAYING COMPOUNDS AFFECTING SMOOTH MUSCLE CONTRACTILE STATE. MENDELSON, MICHAEL E.. 435/7.4; G01N033/573.

29. 20010038837. 08 Jun 01. 08 Nov 01. Myocardial grafts and cellular compositions useful for same. Field, Loren J.. 424/93.7; 435/366 A61K045/00 C12N005/08.

30. 20010037016. 15 Dec 00. 01 Nov 01. Methods and compositions for screening for angiogenesis modulating compounds. Ning, Zhang, et al. 536/23.1; C07H021/02 C07H021/04.

31. 20010031485. 01 Mar 01. 18 Oct 01. Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments. Backer, Marina V., et al. 435/69.4; 435/252.3 514/12 530/399 536/23.5 536/23.7 A61K038/22 C07H021/04 C12N015/09 C07K014/475.

32. 20010024830. 18 Apr 01. 27 Sep 01. Methods for the selective regulation of DNA and RNA transcription and translation by photoactivation. Haselton, Frederick R. III, et al. 435/455; 424/450 435/456 514/44 604/20 A61K048/00 A61K009/127 C12N015/85 C12N015/87.

33. 20010023346. 01 May 01. 20 Sep 01. Method and devices for creating a trap for confining therapeutic drugs and/or genes in the myocardium. Loeb, Marvin P.. 604/508; A61M031/00.

34. 20010021700. 19 Dec 00. 13 Sep 01. 49 human secreted proteins. Moore, Paul A., et al. 514/44; 435/320.1 435/325 435/69.1 435/69.7 435/7.1 514/12 530/350 530/388.2 536/23.5 A61K048/00 G01N033/53 A61K038/16 C07H021/04.

35. 20010016335. 12 Jan 01. 23 Aug 01. Fibroblast growth factor receptor-5. Young, Paul E., et al. 435/69.1; 435/320.1 514/12 514/44 530/350 A61K038/00 A61K031/70 C12P021/06 C07K001/00 C07K014/00 C07K017/00.

36. 20010009904. 30 Apr 98. 26 Jul 01. PROCESS OF DELIVERING A POLYNUCLEOTIDE TO A CELL VIA THE VASCULAR SYSTEM. WOLFF, JON A., et al. 514/44; A61K031/70.

37. 20010008882. 07 Sep 99. 19 Jul 01. PROCESS OF DELIVERING A POLYNUCLEOTIDE INTO A PARENCHYMAL CELL. WOLFF, JON A., et al. 514/44; A61K048/00.

38. 20010007861. 30 Dec 98. 12 Jul 01. METHODS, SYSTEMS, AND KITS FOR INTRAVASCULAR NUCLEIC ACID DELIVERY. NEWMAN, CHRISTOPHER M.H., et al. 514/44; 604/20 604/21 604/22 604/28 A61N001/30 A61K048/00.

39. 20010006781. 28 Aug 98. 05 Jul 01. CANCER CELLS CAPABLE OF TUMORIGENESIS BUT INCAPABLE OF INFILTRATION AND METASTASIS, PROCESS FOR PREPARING THE SAME, AND METHOD FOR SCREENING GENE RELATING TO METASTASIS BY USING THE SAME. TATSUKA, MASAAKI. 435/6; 435/320.1 435/455 536/23.1 C12Q001/68 C07H021/04 C12N005/00 C12N015/85.

40. 6399300. 16 Nov 99; 04 Jun 02. Myocardial grafts and cellular compositions useful for same. Field; Loren J.. 435/6; 435/29 435/366 435/377. C12Q001/68.

41. 6391589. 07 Jan 00; 21 May 02. Human chemokine beta-10 mutant polypeptides. Olsen; Henrik S., et al. 435/69.5; 424/85.1 435/252.3 435/254.11 435/320.1 435/325 435/471 435/71.1 435/71.2 514/12 514/2 514/8 530/324 536/23.1 536/23.5. C12N005/10 C12N015/19 C12N015/63 C07K014/52 A61K038/19.

42. 6372498. 30 Dec 98; 16 Apr 02. Methods, systems, and kits for intravascular nucleic acid delivery. Newman; Christopher M. H., et al. 435/455; 424/93.2 424/93.21 435/325 514/44 536/23.1 604/19 604/22 604/28. C12N012/63 A61M001/00 A61N001/30 A61K048/00 A61B017/20.

43. 6372473. 04 Oct 99; 16 Apr 02. Tissue plasminogen activator-like protease. Moore; Paul A., et al. 435/212; 435/217 530/327 530/328 530/350 530/827 530/828. C12N009/48 C12N009/68 C07K007/09 C07K007/08 C07K004/12.

44. 6359115. 14 Jan 00; 19 Mar 02. Human receptor tyrosine kinase, KDR. Kendall; Richard L., et al. 530/350; 435/69.4 530/402. C07K014/71.

45. 6358954. 09 Nov 99; 19 Mar 02. PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same. Levitzki; Alexander, et al. 514/250; 514/267 544/247 544/251 544/343 544/345. A61K031/495 C07D239/00 C07D491/00 C07D241/36 C07D471/00.

46. 6355786. 29 Oct 99; 12 Mar 02. Purified and isolated protein zero related (PZR) and therapeutic and screening methods using same. Zhao; Zhizhuang. 536/23.1; 435/320.1 435/69.1 435/91.2 530/350 536/23.5. C07H021/02.

47. 6355781. 31 Dec 96; 12 Mar 02. Mammalian growth factor. Basilico; Claudio, et al. 530/399; 530/350. C07K014/475 C07K014/50.

48. 6346382. 01 Jun 99; 12 Feb 02. Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto. Summar; Marshall L., et al. 435/6; 435/91.2 435/91.5 536/23.2 536/23.5 536/24.31 536/24.33 536/25.32. C12Q001/68 C12P019/34 C07H021/04.

49. 6337321. 08 May 98; 08 Jan 02. Enhancement of vascular function by modulation of endogenous nitric oxide production or activity. Cooke; John P., et al. 514/44; 424/93.2 424/93.21 435/320.1 435/325. A61K048/00 A61K035/00 C12N015/85 C12N015/63.

50. 6335010. 30 Jun 97; 01 Jan 02. Gene therapy in coronary angioplasty and bypass. Chien; Shu, et al. 424/93.2; 435/320.1 435/455 514/44. A61K048/00.

Terms	Documents
11 with 12 with L3	161

[Previous Page](#)[Next Page](#)

Search Results - Record(s) 51 through 100 of 161 returned.

51. [6331527](#). 01 Nov 99; 18 Dec 01. Promoter smooth muscle cell expression. Parmacek; Michael S., et al. 514/44; 435/455 435/456 536/24.1 623/1.13 623/1.41. A61K031/70 A61F002/06 C07H021/04 C12N015/85 C12N015/86.

52. [6331524](#). 07 Apr 97; 18 Dec 01. Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy. Scheule; Ronald K., et al. 514/44; 424/450 435/320.1 435/455 435/458. A61K048/00 C12N015/88 C12N015/63.

53. [6328762](#). 27 Apr 99; 11 Dec 01. Prosthetic grafts. Anderson; Diane Lee, et al. 623/1.41; 623/1.1 623/1.39. A61F002/06.

54. [6297221](#). 05 Jan 99; 02 Oct 01. Method for promoting angiogenesis with a nucleic acid construct comprising an SM22.alpha.0 promoter. Parmacek; Michael S., et al. 514/44;. A61K031/70.

55. [6291211](#). 01 Nov 99; 18 Sep 01. Promoter for smooth muscle cell expression. Parmacek; Michael S., et al. 435/69.1; 435/455 435/456 435/91.3 514/44. C12P021/02 C12P019/34 A61K031/70 C12N015/85 C12N015/86.

56. [6290949](#). 28 May 96; 18 Sep 01. Adenoviral vector for inhibiting restenosis. French; Brent A., et al. 424/93.2; 424/93.6 435/320.1 435/456 514/44. A61K048/00 A01N063/00 C12N015/00.

57. [6284743](#). 10 Apr 00; 04 Sep 01. Method for modulating smooth muscle cell proliferation. Parmacek; Michael S., et al. 514/44; 435/375 435/69.1. A61K031/70 C12N005/00 C12P021/06.

58. [6277821](#). 30 Dec 98; 21 Aug 01. Therapeutic uses of bactericidal/permeability-increasing protein dimer products. Ammons; William Steve, et al. 514/12; 424/192.1 435/69.1 435/71.1 514/14 514/2 530/350. A61K038/00 A61K045/05 A61K038/17 C07K014/435.

59. [6268350](#). 07 Jan 00; 31 Jul 01. Polynucleotides for inhibiting metastasis and tumor cell growth. Barbera-Guillem; Emilio. 514/44; 536/23.1 536/23.5 536/24.5. A61K048/00 C07H021/02 C07H021/04.

60. [6265387](#). 21 Nov 97; 24 Jul 01. Process of delivering naked DNA into a hepatocyte via bile duct. Wolff; Jon A., et al. 514/44; 435/325 435/455 435/69.1. A61K035/00 C12N015/09 C12N015/85 C12N015/00.

61. [6258787](#). 30 Jul 97; 10 Jul 01. Treatment of vascular injury. Isner; Jeffrey M.. 514/44; 435/320.1 435/455 435/69.1 435/69.4 435/69.6 435/69.8. A01N043/04 A61K031/70 C12N015/63 C12N015/00.

62. [6258557](#). 14 Mar 97; 10 Jul 01. Smooth muscle cell LIM promoter. Lee; Mu-En, et al. 435/69.1; 435/320.1 435/325 435/455 435/6 514/44 536/23.1 536/23.5 536/24.31. C12N015/63 C12N015/09 C12N015/00 C12N005/00.

63. [6245512](#). 05 Mar 99; 12 Jun 01. Promoter for VEGF receptor. Williams; Lewis T., et al. 435/6;

435/320.1 435/361 435/7.1 530/350 536/23.5. C12Q001/68 C07H021/04.

64. [6242258](#). 05 Jan 00; 05 Jun 01. Methods for the selective regulation of DNA and RNA transcription and translation by photoactivation. Haselton, III; Frederick R., et al. 435/455; 435/456 435/458 435/468 435/471 514/44. C12N015/63 C12N015/85 C12N015/86 C12N015/88 A61K031/70.

65. [6228391](#). 10 Dec 98; 08 May 01. Amidine derivatives and drug carriers comprising the same. Shimizu; Kazuhiro, et al. 424/450; 424/1.21 424/9.321 424/9.51 424/94.3 564/225 564/244. C07C257/14 C07C335/32 C07C335/36 A61K047/16 A61K009/127.

66. [6224566](#). 04 May 99; 01 May 01. Method and devices for creating a trap for confining therapeutic drugs and/or genes in the myocardium. Loeb; Marvin P.. 604/22; 604/20 604/239 606/15 606/16. A61B017/20.

67. [6217912](#). 13 Jul 99; 17 Apr 01. Polyester analogue of poly-L-lysine as a soluble, biodegradable gene delivery carrier. Park; Jong Sang, et al. 424/501; 424/489 435/325 435/440 514/44. A61K047/14 A61K048/00 C12N015/85 C12N015/00.

68. [6204011](#). 17 Jun 98; 20 Mar 01. Human receptor tyrosine kinase, KDR. Kendall; Richard L., et al. 435/69.1; 435/252.3 435/254.11 435/320.1 435/325 530/350 536/23.1 536/23.5. C12N015/12.

69. [6203991](#). 20 Aug 99; 20 Mar 01. Inhibition of smooth muscle cell migration by heme oxygenase I. Nabel; Gary J., et al. 435/6; 435/320.1 435/458 514/44 536/23.1. C12Q001/68 C12N015/63 C12N015/88 A61K048/00 C07H021/04.

70. [6177274](#). 20 May 99; 23 Jan 01. Hepatocyte targeting polyethylene glyco-grafted poly-L-lysine polymeric gene carrier. Park; Jong Sang, et al. 435/455; 514/44 536/24.5. A01N043/04 C07H021/04 C12P019/34.

71. [6174871](#). 10 Aug 98; 16 Jan 01. Gene therapies for enhancing cardiac function. Hammond; H. Kirk, et al. 514/44; 424/93.6 435/320.1 536/23.5. A01N043/04 A01N063/00 A61K031/70 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74.

72. [6149936](#). 28 Jul 98; 21 Nov 00. DNA expression vectors for the use in the gene therapeutic treatment of vascular disorders. Schrader; Jurgen, et al. 424/450; 514/44. A61K003/127 A61K031/708.8.

73. [6146887](#). 28 Jul 98; 14 Nov 00. DNA expression vectors for use in the gene therapeutic treatment of vascular disorders. Schrader; Jurgen, et al. 435/320.1; 435/440 435/69.1 514/12 514/44 536/23.2 536/23.5. C12N015/00.

74. [6130207](#). 05 Nov 97; 10 Oct 00. Cell-specific molecule and method for importing DNA into a nucleus. Dean; David Andrew, et al. 514/44; 424/93.21 435/320.1 435/325 435/455 435/458 536/23.1 536/24.1. A61K048/00.

75. [6114311](#). 26 Feb 99; 05 Sep 00. Method for modulating smooth muscle cell proliferation. Parmacek; Michael S., et al. 514/44;. A61K031/70.

76. [6100242](#). 29 Dec 97; 08 Aug 00. Gene therapies for enhancing cardiac function. Hammond; H. Kirk, et al. 514/44; 424/93.21 435/320.1. A61K048/00.

77. 6090618. 07 Oct 96; 18 Jul 00. DNA constructs and viral vectors comprising a smooth muscle promoter. Parmacek; Michael S., et al. 435/320.1; 536/23.1 536/23.5 536/24.1. C12N015/63 C12N015/11 C12N015/12.

78. 6090580. 02 Jan 98; 18 Jul 00. Interferon responsive transcript (IRT-1). Autieri; Michael V.. 435/69.1; 435/252.33 435/320.1 435/325 530/350 536/23.1 536/23.5. C12P021/06 C07H021/04.

79. 6077933. 10 May 99; 20 Jun 00. Repressor Kruppel-like factor. Lee; Mu-En, et al. 530/300; 530/324 530/350. C07K014/47.

80. 6040157. 13 Mar 98; 21 Mar 00. Vascular endothelial growth factor 2. Hu; Jing-Shan, et al. 435/69.4; 435/243 435/320.1 435/325 435/7.1 530/399 536/23.51. C12N015/18 C12N015/63 C12N001/21 C12N005/00.

81. 6034071. 16 Sep 94; 07 Mar 00. Mutant activated G.sub.S .alpha. and adenylyl cyclase 2 for use as therapeutic agents. Iyengar; Srinivas Ravi V.. 514/44; 536/23.5. A61K047/36.

82. 6033665. 01 Jun 95; 07 Mar 00. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells. Yednock; Theodore A.. 424/130.1; 424/141.1 424/143.1 424/144.1 514/2 530/300 530/350 530/387.1 530/388.22 530/389.1 530/395. A61K038/00 A61K039/395.

83. 6027892. 16 Dec 97; 22 Feb 00. Compositions and methods for reducing radiation and drug resistance in cells. Chang; Esther H., et al. 435/6; 435/194 435/371 435/375 536/23.1 536/24.31 536/24.5. C12Q001/68 C12N009/00 C12N015/85 C07H021/04.

84. 6022874. 23 Dec 98; 08 Feb 00. Piperazine based cytoflectins. Wheeler; Carl J.. 514/247; 424/1.21 424/417 424/420 424/812 424/9.321 427/2.14 514/2 514/252.12 514/44 544/358 544/359. A01N043/58 A01N025/26 A61K039/00.

85. 6017758. 20 Feb 98; 25 Jan 00. DMNPE caged nucleic acid and vector. Haselton, III; Frederick R., et al. 435/325; 435/243 435/320.1 435/410 536/23.1. C12N015/63 C12N001/00 C12N005/10 C12N015/11.

86. 6015711. 28 Jul 98; 18 Jan 00. Smooth muscle 22.alpha. promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells. Olson; Eric N., et al. 435/375; 435/320.1 514/44 536/23.1 536/23.5 536/24.1 536/24.5. A61K048/00.

87. 6015671. 21 Nov 97; 18 Jan 00. Myocardial grafts and cellular compositions. Field; Loren J.. 435/6; 435/354 435/366 435/377 435/465. C12Q001/68.

88. 6001644. 22 Aug 94; 14 Dec 99. Mammalian transformation complex comprising a lipid carrier and DNA encoding CFTR. Debs; Robert J., et al. 435/320.1; 128/203.22 424/450 435/458 514/44 600/243 600/249 601/1. C12N015/00 C12N015/63.

89. 5994317. 09 Apr 96; 30 Nov 99. Quaternary cytoflectins. Wheeler; Carl J.. 514/44; 424/1.21 424/417 424/420 424/9.321 427/2.14 435/325 435/455 435/458 435/6 562/899 564/281. A61K048/00.

90. [5986055](#). 13 Nov 97; 16 Nov 99. CDK2 interactions. Yang; Meijia, et al. 530/350; 530/300. C07K014/47.

91. [5981487](#). 03 Oct 97; 09 Nov 99. Method of inhibiting smooth muscle cell proliferation. Koch; Walter J., et al. 514/12; 514/2 514/44. A61K031/70.

92. [5980886](#). 17 Mar 97; 09 Nov 99. Recombinant vectors for reconstitution of liver. Kay; Mark A., et al. 424/93.21; 424/93.1 424/93.2 514/44. A01N063/00 A01N043/04.

93. [5962427](#). 12 Apr 96; 05 Oct 99. In vivo gene transfer methods for wound healing. Goldstein; Steven A., et al. 514/44; 424/93.21 435/320.1 435/325 435/455 435/458 536/24.5. A61K048/00.

94. [5958403](#). 11 Jul 94; 28 Sep 99. Methods and compounds for prevention of graft rejection. Strom; Terry, et al. 424/93.21; 514/44. C12N015/63 A61K048/00.

95. [5955441](#). 13 Aug 96; 21 Sep 99. Genetic inhibition of complement mediated inflammatory response. Sims; Peter J., et al. 514/44; A01N043/04.

96. [5948767](#). 12 Jul 96; 07 Sep 99. Cationic amphiphile/DNA complexes. Scheule; Ronald K., et al. 514/44; 435/320.1 435/325 435/455 435/458. A61K048/00.

97. [5945452](#). 07 Feb 97; 31 Aug 99. Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity. Cooke; John P., et al. 514/564; 424/439 424/441 426/648 426/656 514/565. A23L001/305 A61K009/00 A61K031/195.

98. [5932580](#). 01 Dec 97; 03 Aug 99. PDGF receptor kinase inhibitory compounds their preparation and compositions. Levitzki; Alexander, et al. 514/249; 514/250 544/344 544/345 544/353. A01N043/58 C07D241/36 C07D471/00.

99. [5928941](#). 07 Oct 97; 27 Jul 99. Repressor kruppel-like factor. Lee; Mu-En, et al. 435/325; 435/243 435/320.1 435/410 536/23.5. C12N001/00 C12N005/10 C12N015/12 C12N015/63.

100. [5922687](#). 07 Nov 96; 13 Jul 99. Intracellular delivery of nucleic acids using pressure. Mann; Michael J., et al. 514/44; 435/440 435/455. A61K048/00.

[Generate Collection](#)[Print](#)

Terms	Documents
l1 with l2 with L3	161

[Previous Page](#) [Next Page](#)

Search Results - Record(s) 101 through 150 of 161 returned.

101. 5916763. 09 Nov 95; 29 Jun 99. Promoter for VEGF receptor. Williams; Lewis T., et al. 435/69.1; 435/320.1 435/325 435/366 435/455 435/471 435/70.1 536/24.1. C07H021/04 C12P021/06 C12N015/00 C12N005/00.

102. 5891459. 09 Nov 95; 06 Apr 99. Enhancement of vascular function by modulation of endogenous nitric oxide production or activity. Cooke; John P., et al. 424/439; 424/441 426/648 426/656 514/564 514/565. A23L001/305 A61K009/00 A61K031/195.

103. 5869462. 16 Feb 95; 09 Feb 99. Inhibition of proliferation of vascular smooth muscle cell. Dzau; Victor J.. 514/44; 424/450 435/375 435/377 536/24.3 536/24.31 536/24.33 536/24.5. A61K048/00 C12N005/10 C07N021/00.

104. 5861397. 03 Oct 96; 19 Jan 99. Piperazine based cytofectins. Wheeler; Carl J.. 514/44; 424/1.21 424/417 424/420 424/812 424/9.321 427/2.14 514/247 514/252.1 514/252.16 514/252.2 514/254.01 514/254.05 514/254.09 544/358 544/359. A01N043/58 A01N025/26 A61K031/50 A61K039/00.

105. 5856302. 16 Dec 96; 05 Jan 99. Therapeutic uses of bactericidal/permeability-increasing protein dimer products. Ammons; William Steve, et al. 514/12; 424/192.1 514/2 530/350. C07K014/435 A61K038/17.

106. 5851521. 30 Sep 96; 22 Dec 98. Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis. Branellec; Didier, et al. 424/93.2; 435/320.1 435/325 435/375 435/456 514/44 536/23.5. A61K035/76 A61K048/00 C12N015/86 C12N015/63.

107. 5846720. 15 Aug 96; 08 Dec 98. Methods of determining chemicals that modulate expression of genes associated with cardiovascular disease. Foulkes; J. Gordon, et al. 435/6; 435/320.1 435/69.8 435/91.5. C12Q001/68 C12P019/34 C12N015/85 C07H021/04.

108. 5837534. 14 Nov 95; 17 Nov 98. Smooth muscle 22.alpha. promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells. Olson; Eric N., et al. 435/320.1; 536/23.1 536/23.5 536/24.1 536/24.5. C07H021/04 C12N015/00 C12N015/09 C12N015/11.

109. 5830879. 02 Oct 95; 03 Nov 98. Treatment of vascular injury using vascular endothelial growth factor. Isner; Jeffrey M.. 514/44; 435/320.1 435/69.4 435/69.6 435/69.8 435/91.2 536/23.5 536/23.51. A01N043/04 A61K031/70 C12N015/63.

110. 5827703. 19 May 94; 27 Oct 98. Methods and composition for in vivo gene therapy. Debs; Robert James, et al. 514/44; 424/417 424/420 424/450 435/325 435/354 435/375 435/458 435/6 435/69.1. C12N015/64 A61K009/127 A61K048/00 C12Q001/68.

111. 5792453. 07 Jun 95; 11 Aug 98. Gene transfer-mediated angiogenesis therapy. Hammond; H. Kirk, et al. 424/93.21; 435/320.1 435/366 536/23.5. A01N063/00.

112. 5785965. 15 May 96; 28 Jul 98. VEGF gene transfer into endothelial cells for vascular prosthesis. Pratt; Richard E., et al. 424/93.21; 424/93.1 424/93.2 435/325 435/455 435/456. A01N063/00 C12N015/00.

113. 5750659. 03 May 93; 12 May 98. Mammalian growth factor. Basilico; Claudio, et al. 530/399; 530/350. C07K014/475 C07K014/50.

114. 5747340. 28 Feb 95; 05 May 98. Targeted gene expression using preproendothelin-1 promoters. Harats; Dror, et al. 435/456; 435/320.1 435/375 435/458 514/44 536/24.1. C12N005/00 C12N015/00 C07H021/04.

115. 5733727. 07 Jun 95; 31 Mar 98. Myocardial grafts and cellular compositions. Field; Loren J.. 435/6; 435/354 435/377 435/465. C12Q001/68 C12N005/10.

116. 5728534. 19 Jul 96; 17 Mar 98. Methods for identifying cardiovascular therapeutic agents. Mendelsohn; Michael E., et al. 435/7.1; 435/244 435/325 435/375 435/69.1 435/7.72 435/7.8. G01N033/53 G01N033/566 C12N015/09.

117. 5723324. 30 Sep 96; 03 Mar 98. Apparatus and method for electrostatic endothelial cell seeding and DNA transfection in a vascular prosthesis. Bowlin; Gary L., et al. 435/173.6; 424/423 435/173.1 435/173.5 435/174 435/177 435/180 435/283.1 435/285.2 435/395 623/920. C12N013/00 C12N011/00 C12N011/02 C12N005/00.

118. 5703038. 06 Jun 95; 30 Dec 97. Therapeutic uses of bactericidal-permeability-increasing protein dimer products. Ammons; William Steve, et al. 514/2; 514/12 530/350. A61K038/17 A61K038/02 C07K014/435 C07K002/00.

119. 5676954. 08 May 95; 14 Oct 97. Method of in vivo delivery of functioning foreign genes. Brigham; Kenneth L.. 424/450; 435/458 536/23.1. C17N015/00 A61K009/127 C07H021/02.

120. 5663314. 18 Apr 95; 02 Sep 97. Human signal transduction MAPK kinase. Seger; Rony, et al. 536/23.2.; C07H021/04.

121. 5660855. 10 Feb 95; 26 Aug 97. Lipid constructs for targeting to vascular smooth muscle tissue. Male-Brune; Roxanne. 424/450; 514/24 514/9. A61K009/127 A61K038/16 A61K038/00 A61K031/70.

122. 5658565. 24 Jun 94; 19 Aug 97. Inducible nitric oxide synthase gene for treatment of disease. Billiar; Timothy R., et al. 424/93.21; 424/93.1 424/93.2 435/189 435/191 435/235.1 435/320.1 514/44 536/23.1 536/23.2 536/23.5. A61K048/00.

123. 5652225. 03 Jul 96; 29 Jul 97. Methods and products for nucleic acid delivery. Isner; Jeffrey M.. 514/44; 424/93.2 435/320.1 536/23.5 536/23.51 604/507 604/522. A01N047/40.

124. 5646250. 01 Nov 94; 08 Jul 97. Cadherin polypeptides. Suzuki; Shintaro. 530/350; 435/69.1 530/300 530/395. C07K014/435 C12N015/12.

125. 5639634. 01 Nov 94; 17 Jun 97. Cadherin polynucleotides. Suzuki; Shintaro. 435/69.1;

435/252.3 435/254.11 435/320.1 435/353 435/356 435/366 536/23.5. C12N015/12.

126. 5631237. 10 May 94; 20 May 97. Method for producing in vivo delivery of therapeutic agents via liposomes. Dzau; Victor J., et al. 514/44; 264/4.1 264/4.3 264/4.6 424/417 424/450 428/402.2. A61K048/00 A61K009/127.

127. 5602301. 16 Nov 94; 11 Feb 97. Non-human mammal having a graft and methods of delivering protein to myocardial tissue. Field; Loren J.. 800/8; 424/93.21 424/93.7 435/69.1. C12N005/00 A61K048/00 A01N063/00 C12P021/06.

128. 5599676. 14 Oct 94; 04 Feb 97. Method for isolating a novel receptor for .alpha.4 integrins. Vonderheide; Robert H., et al. 435/7.2; 435/252.3 435/252.33 435/254.11 435/320.1 435/69.1 435/91.1 530/387.1 536/23.1. C12Q001/02 C12N015/12 C07K016/00.

129. 5597725. 26 Jan 94; 28 Jan 97. Cadherin-specific antibodies and hybridoma cell lines. Suzuki; Shintaro. 435/328; 435/70.21 530/387.3 530/388.1 530/388.22 530/389.1 530/389.2. C12N005/12 A61K051/10 C07K016/00 C07K016/28.

130. 5580722. 07 Feb 92; 03 Dec 96. Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease. Foulkes; J. Gordon, et al. 435/6; 435/91.1 435/91.2. C12P019/34 C12Q001/68.

131. 5573940. 07 Jul 94; 12 Nov 96. Cells expressing high levels of CD59. Sims; Peter J., et al. 435/362; 424/93.21 435/69.1. C12N005/10.

132. 5571523. 09 Mar 95; 05 Nov 96. Antioxidant-induced apoptosis in vascular smooth muscle cells. Lee; Mu-En, et al. 424/423;. A61F002/02.

133. 5447913. 11 Mar 94; 05 Sep 95. Therapeutic uses of bactericidal/permeability-increasing protein dimer products. Ammons; William S., et al. 514/12; 514/21 530/350. C07K014/52 C07K014/435 A61K038/16.

134. 5219739. 27 Jul 90; 15 Jun 93. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF.sub.120 and hVEGF.sub.121. Tischer; Edmund G., et al. 435/69.4; 435/320.1 435/69.1 530/399 536/23.5 536/23.51. C12N005/10 C12N015/18.

135. JP 11080033 A. 13 Jul 98. 23 Mar 99. TRANSFECTION SYSTEM, ITS PRODUCTION AND ITS USE ON SOMATIC CELL GENE THERAPY. SCHRADER, JUERGEN. A61K048/00; C12N009/00 C12N015/09.

136. JP 09173060 A. 28 Dec 95. 08 Jul 97. ESTABLISHMENT OF CULTURED STRAIN OF IMMORTALIZED HUMAN CORONARY ARTERIAL VASCULAR ENDOTHELIAL CELL AND PRODUCTION OF CARDIOVASCULAR THERAPEUTIC AGENT USING THE SAME. SASAKURI, YASUYUKI. C12N005/10; A61K035/12.

137. WO 9858542 A1. 20 Jun 97. 30 Dec 98. A PROCESS OF DELIVERING A POLYNUCLEOTIDE VIA THE VASCULAR SYSTEM. WOLFF, JON A, et al. A01N043/04; A61K031/70 C12N015/63.

138. US 5723324 A. 30 Sep 96. 03 Mar 98. Apparatus and method for electrostatic endothelial cell seeding and DNA transfection in a vascular prosthesis. BOWLIN, GARY L, et al. C12N013/00; C12N011/00 C12N011/02 C12N005/00.

139. WO 9713849 A1. 11 Oct 96. 17 Apr 97. APPARATUS AND METHOD FOR ELECTROSTATIC ENDOTHELIAL CELL SEEDING AND DNA TRANSFECTION. BOWLIN, GARY L, et al. C12N011/00; C12N011/02 C12N011/08 C12N013/00 C12N005/00 C12M003/00 C12M003/04 A61F002/04.

140. EP 682113 A2. 08 May 95. 15 Nov 95. Polypeptide produced in an endothelial cell line and DNA encoding it.. SHIBAYAMA, SHIRO C O MINASE RES, et al. C12N015/12; C07K014/705 C12N015/85 C12N005/10 C07K016/28 A61K038/22.

141. WO 9405334 A1. 02 Sep 93. 17 Mar 94. VASCULAR IN VIVO EXPRESSION OF MACROPHAGE COLONY STIMULATING FACTOR. TAYLOR, JOHN M, et al. A61K048/00;.

142. US 6267954 B1. Delivering polypeptide to ocular cell in vivo, for treating photoreceptor degeneration retinopathies or cancers, involves implanting composition having encapsulated cells which produce polypeptide, in eye of subject. ABITBOL, M, et al. A01N063/00 A61K009/14.

143. US 2001004636 A1. Transfection of genetic material into mammalian cells useful e.g. to deliver therapeutic polynucleotides in gene therapy, by inserting the genetic material into a blood vessel and increasing the permeability of the vessel. BUDKER, V G, et al. A01N043/04 A61K031/70 C07H021/04.

144. EP 1180000 A1, WO 200064377 A1, AU 200044977 A, US 6328762 B1, US 20020026235 A1. New prosthetic grafts for bypass, replacement or repair of vessels and organs that are in contact with blood flow which have adhered cells transfected with nucleic acids to increase patency. ANDERSON, D L, et al. A61F002/06.

145. EP 1192168 A1, WO 200063221 A2, AU 200043658 A. Novel galectin polynucleotides and polypeptides, used in the diagnosis and treatment of cancers, autoimmune disorders, and inflammatory disorders, and to screen for antagonists and agonists. GENTZ, R L, et al. A61K038/00 A61K038/04 A61K038/05 A61K038/06 A61K038/07 A61K038/08 A61K038/10 A61K038/14 A61K038/16 C07H005/00 C07H005/04 C07H019/00 C07H021/00 C07H021/02 C07H021/04 C07K001/00 C07K001/04 C07K004/00 C07K004/12 C07K005/00 C07K016/00 C07K016/18 C07K017/00 C07K017/02 C07K017/04 C07K017/08 G01N033/53 G01N033/567.

146. BR 200008397 A, WO 200048518 A1, AU 200035971 A, EP 1158909 A1. Enhancing cellular absorption of a delivered substance into a target region comprises applying the substance and ultrasound to the target area, used to reduce the amount of vascular intimal hyperplasia in humans after vascular injury. BRISKEN, A F, et al. A61B017/20.

147. WO 200043498 A2, AU 200028520 A, EP 1147179 A2. Composition comprising an enriched population of human liver progenitors, useful for treatment of liver disorders such as cirrhosis, fibrosis, hepatitis, chronic liver failure, and cancer, and for production of a bioartificial liver. KUBOTA, H, et al. A01N001/02 A61K035/407 A61P001/16 A61P035/00 C12N005/00 C12N005/08 C12N005/10.

148. WO 200015800 A2, AU 9963876 A. Introducing a plant Rac gene to an animal, useful in

gene therapy to treat patients with infections and to prevent reperfusion injuries and blood vessel damage.
DUVICK, J P, et al. A01K067/027 A61K048/00 A61P007/00 C07K014/415 C12N015/29.

149. EP 1105116 A1, WO 200009119 A1, AU 9952958 A . Treatment of Alzheimer's disease using dipeptide ester derivatives containing an N-hydroxysuccinamido group, inhibiting beta-amyloid peptide production leading to cerebral neuritic plaques. AYSCOUGH, A P, et al. A61K031/215 A61K031/22 A61K031/38 A61P025/28.

150. AU 9736594 A, WO 9902190 A1 . In vivo transfection of tissue with retinoblastoma gene - formulated with spermine cholesterol carbamate as cationic amphiphile to facilitate transport, used for gene therapy of cancers and tumours. BAGLEY, R G, et al. A61K048/00.

[Generate Collection](#)

[Print](#)

Terms	Documents
l1 with l2 with L3	161

[Previous Page](#) [Next Page](#)

[Generate Collection](#)[Print](#)

Search Results - Record(s) 151 through 161 of 161 returned.

151. AU 742898 B, WO 9839354 A1, AU 9863403 A, US 5858990 A, EP 981536 A1. Use of Fas ligand molecules - for treating conditions characterised by excessive proliferation of smooth muscle cells, e.g. arteriosclerosis, vascular injury or reperfusion. WALSH, K. A61K048/00 C07H021/02 C07H021/04 C12N005/06 C12N015/00 C12N015/11 C12P021/02 C12Q001/68.

152. US 6335010 B1, WO 9819686 A1, AU 9851739 A. Treating disorders involving vascular cells - by inhibiting Ras signal transduction pathway, using nucleic acid encoding signalling incompetent protein in the pathway. CHIEN, S, et al. A61K031/70 A61K048/00 C07H021/00.

153. US 6375929 B1, WO 9813071 A1, AU 9746503 A, EP 928203 A1, JP 2001501471 W, AU 738806 B. Inhibition of angiogenesis, particularly in tumours - by using DNA expressing a soluble form of a tyrosine kinase receptor which forms a dimer with a vascular endothelial growth factor. BETT, A J, et al. A61K031/711 A61K048/00 A61K049/00 A61P017/06 A61P027/02 A61P029/00 A61P035/00 A61P035/04 C12N007/00 C12N015/09 C12N015/85 C12N015/86 C12N015/861 C12Q001/68 C12Q001/70.

154. US 5723324 A. Electrically assisted modification of vascular grafts - with endothelial cells and plasmid DNA. BOWLIN, G L, et al. C12N005/00 C12N011/00 C12N011/02 C12N013/00.

155. AU 738083 B, WO 9802190 A2, AU 9736590 A, EP 954338 A2, JP 2000516209 W. Transfection of blood vessel in vivo - using composition comprising DNA molecule and cationic amphiphile. BAGLEY, R G, et al. A61K031/7105 A61K031/711 A61K038/00 A61K038/22 A61K047/18 A61K047/28 A61K047/48 A61K048/00 A61P007/00 A61P009/00 A61P011/00 A61P021/00 A61P025/00 A61P035/00.

156. DE 19620308 A1, EP 807688 A2. Vector for specific gene expression in vascular smooth muscle - contains smooth muscle myosin heavy chain gene promoter. FRANZ, W, et al. A01K067/027 A61K031/70 A61K048/00 C12N005/10 C12N015/79 C12N015/85 C12N015/88 C12Q001/68.

157. US 6245512 B1, WO 9717359 A1, AU 9674466 A, US 5916763 A. Vascular endothelial growth factor receptor promoter - useful to develop products to treat, e.g. tumours, hypertension, thrombosis, atherosclerosis or inflammatory diseases. MORISHITA, K, et al. A61K048/00 C07H021/04 C12N005/00 C12N015/00 C12N015/63 C12N015/85 C12N015/86 C12P021/06 C12Q001/68 G01N033/53.

158. JP 11514869 W, WO 9713849 A1, AU 9675954 A, US 5714359 A, GB 2322634 A, DE 19681598 T, GB 2322634 B. Appts. for seeding a surface with cells by transient alteration of surface charge - optionally also for transfecting the cells with DNA, especially for treatment of vascular prostheses with endothelial cells. BOWLIN, G L, et al. A61F002/04 A61F002/06 C12M001/14 C12M001/42 C12M003/00 C12M003/04 C12N005/00 C12N005/10 C12N011/00 C12N011/02 C12N011/08 C12N013/00 C12N015/09 C12N015/09 C12R001:91.

159. WO 9610335 A1, US 5552309 A. Compsn. contg. expression vehicle (e.g. plasmid) and polyol - useful for introduction of vehicle into cells at greater efficiency of transduction and treating blood

vessel wall diseases, e.g. ischaemia or hypertension. MARCH, K L. A01J021/00 A01N063/00
A01N065/00 A61K048/00 C12N005/00 C12N015/00.

160. WO 9405334 A1, AU 9348450 A. Transplanting vascular cells expressing macrophage colony stimulating factor into vascular tissue - for therapy and to generate animal model for studying the localised effects of MCSF.. LAVER, S J, et al. A61K048/00.

161. US N7679674 N, WO 9217569 A1, AU 9217659 A, EP 578769 A1, JP 06509467 W, EP 578769 A4. Immortalised primate micro-vascular cell line - designated CDC-EU-HMEC-1, prep'd. by transfection of HDMEC with DNA encoding SV40 large T antigen. ADES, E W, et al. C12N000/01 C12N005/16 C12N005/22 C12N015/37 C12N015/64.

[Generate Collection](#)

[Print](#)

Terms	Documents
I1 with I2 with L3	161

[Previous Page](#)

[Next Page](#)